← Back to All US Stocks

DRTSW Stock Analysis 2026 - Alpha Tau Medical Ltd. AI Rating

DRTSW Nasdaq Surgical & Medical Instruments & Apparatus L3 CIK: 0001871321
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2026-03-23
SELL
95% Conf
Pending
Analysis scheduled

📊 DRTSW Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: SELL with 95% confidence

Is DRTSW a Good Investment? Thesis Analysis

Claude

Alpha Tau Medical Ltd. presents an uninvestable profile due to complete absence of reported financial data across all fundamental metrics. With zero revenue reported, no profitability indicators, and negligible insider activity, there is insufficient evidence of operational viability or financial substance to support any investment thesis.

Why Buy DRTSW? Key Strengths

Claude
  • -No strengths identified

DRTSW Investment Risks to Consider

Claude
  • ! Complete lack of revenue reporting indicates either pre-revenue status or severe financial reporting deficiencies
  • ! Absence of all balance sheet, cash flow, and profitability metrics prevents fundamental analysis of financial health
  • ! Zero insider Form 4 filings in last 90 days suggests minimal management confidence or activity
  • ! Only 1 metric available indicates severe data gaps in SEC filings or company has not yet filed required financial statements
  • ! Inability to assess liquidity, solvency, or operational efficiency due to missing financial statements

Key Metrics to Watch

Claude
  • * Quarterly revenue recognition and growth trajectory once financial data becomes available
  • * Cash burn rate and runway given apparent pre-revenue or non-reporting status
  • * Balance sheet composition and capital structure once fully disclosed in SEC filings

DRTSW Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

DRTSW Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

DRTSW vs Healthcare Sector

How Alpha Tau Medical Ltd. compares to Healthcare sector averages

Net Margin
DRTSW 0.0%
vs
Sector Avg 12.0%
DRTSW Sector
ROE
DRTSW 0.0%
vs
Sector Avg 15.0%
DRTSW Sector
Current Ratio
DRTSW 0.0x
vs
Sector Avg 2.0x
DRTSW Sector
Debt/Equity
DRTSW 0.0x
vs
Sector Avg 0.6x
DRTSW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is DRTSW Overvalued or Undervalued?

Based on fundamental analysis, Alpha Tau Medical Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

DRTSW Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

DRTSW Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

DRTSW SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for Alpha Tau Medical Ltd. (CIK: 0001871321)

Frequently Asked Questions about DRTSW

What is the AI rating for DRTSW?

Alpha Tau Medical Ltd. (DRTSW) has an AI rating of SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are DRTSW's key strengths?

Claude: .

What are the risks of investing in DRTSW?

Claude: Complete lack of revenue reporting indicates either pre-revenue status or severe financial reporting deficiencies. Absence of all balance sheet, cash flow, and profitability metrics prevents fundamental analysis of financial health.

What is DRTSW's revenue and growth?

Alpha Tau Medical Ltd. reported revenue of N/A.

Does DRTSW pay dividends?

Alpha Tau Medical Ltd. does not currently pay dividends.

Where can I find DRTSW SEC filings?

Official SEC filings for Alpha Tau Medical Ltd. (CIK: 0001871321) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DRTSW's EPS?

Alpha Tau Medical Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is DRTSW a good stock to buy right now?

Based on our AI fundamental analysis in March 2026, Alpha Tau Medical Ltd. has a SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is DRTSW stock overvalued or undervalued?

Valuation metrics for DRTSW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy DRTSW stock in 2026?

Our dual AI analysis gives Alpha Tau Medical Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is DRTSW's free cash flow?

Alpha Tau Medical Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does DRTSW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2026-03-23 | Powered by Claude AI